UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040833
Receipt number R000046580
Scientific Title Associations with QTc interval and atherosclerosis in patients with type 2 diabetes
Date of disclosure of the study information 2020/07/01
Last modified on 2023/08/30 13:45:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Associations with QTc interval and atherosclerosis in patients with type 2 diabetes

Acronym

Associations with QTc interval and atherosclerosis in patients with type 2 diabetes

Scientific Title

Associations with QTc interval and atherosclerosis in patients with type 2 diabetes

Scientific Title:Acronym

Associations with QTc interval and atherosclerosis in patients with type 2 diabetes

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Prolonged QTc interval is associated with fatal cardiac arrhythmia and mortality. The aim of this study is to investigate association with QTc interval and atherosclerosis in patients with type 2 diabetes

Basic objectives2

Others

Basic objectives -Others

The aim of this study is to investigate association with QTc interval and atherosclerosis markers such as ABI, CAVI, Carotid artery ultrasonography, FMD in patients with type 2 diabetes.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

QTc interval, ABI, CAVI, Carotid artery ultrasonography, FMD

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

Patients with type 2 diabetes who were admitted to Nippon Medical School Hospital for glycemic control during April 2009 to March 2013.

Key exclusion criteria

Atrial fibrillation, uncontrolled endocrine disease, receiving steroid therapy, hemodialysis, infection, malignant tumor under treatment and ketoacidosis.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hitoshi
Middle name
Last name Sugihara

Organization

Nippon Medical School Hospital

Division name

Department of Diabetes, Endocrinology and Metabolism

Zip code

113-8603

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan

TEL

03-3822-2131

Email

hitoshi@nms.ac.jp


Public contact

Name of contact person

1st name Hitoshi
Middle name
Last name Sugihara

Organization

Nippon Medical School Hospital

Division name

Department of Diabetes, Endocrinology and Metabolism

Zip code

113-8603

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan

TEL

03-3822-2131

Homepage URL


Email

hitoshi@nms.ac.jp


Sponsor or person

Institute

Nippon Medical School Hospital

Institute

Department

Personal name



Funding Source

Organization

Nippon Medical School Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nippon Medical School hospital

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan

Tel

03-3822-2131

Email

inq-ccr@nms.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

133

Results

Analysis of the correlation between the markers of arteriosclerosis such as ABI, CAVI, carotid mean IMT, carotid max IMT, and FMD and corrected QT interval showed that only FMD had a statistically significant correlation with corrected QT interval. In multiple regression analysis, FMD was also statistically significantly associated with corrected QT interval.

Results date posted

2023 Year 08 Month 30 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 04 Month 01 Day

Date of IRB

2019 Year 06 Month 01 Day

Anticipated trial start date

2019 Year 06 Month 01 Day

Last follow-up date

2022 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

retrospective review


Management information

Registered date

2020 Year 06 Month 19 Day

Last modified on

2023 Year 08 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046580


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name